Valuation: Lundbeck

Market Cap 40.51B 6.17B 5.41B 5B 4.68B 8.75B 583B 8.95B 59.98B 23.21B 288B 23.18B 22.67B 998B P/E 2026 *
9.32x
P/E 2027 * 9.12x
Enterprise Value 44.61B 6.8B 5.96B 5.5B 5.15B 9.64B 642B 9.85B 66.04B 25.56B 317B 25.52B 24.96B 1,099B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.57x
Free-Float
30.76%
Yield 2026 *
3.51%
Yield 2027 * 3.59%
1 day-1.66%
1 week+1.71%
Current month-2.84%
1 month-1.14%
3 months+9.09%
6 months-2.59%
Current year-2.34%
1 week 5.55
Extreme 5.55
5.76
1 month 5.54
Extreme 5.545
6.03
Current year 4.85
Extreme 4.852
6.26
1 year 4.48
Extreme 4.476
6.4
3 years 3.67
Extreme 3.666
6.62
5 years 3.26
Extreme 3.259
8.85
10 years 3.26
Extreme 3.259
8.85
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 66 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%+1.71% - - 6.18B
-0.04%+1.72%+5.20%+83.89% 89.39B
+1.35%+7.28%+42.31%+153.62% 55.72B
-1.07%+0.36%-6.10%+237.80% 22B
-3.11%-3.90%-13.86%-27.43% 7.63B
-5.31%-6.81%-34.61%-37.49% 6.81B
-1.19%-3.60%-15.29%-33.23% 6.28B
-0.23%+1.72%-0.75%+20.46% 5.28B
-4.35%-4.35%-9.77%-16.90% 3.39B
+0.50%+1.31%+12.88%+11.32% 3.32B
Average -1.51%-0.95%-2.22%+43.56% 22.2B
Weighted average by Cap. -0.21%+1.91%+11.29%+103.61%

Financials

2026 *2027 *
Net sales 25.7B 3.92B 3.44B 3.17B 2.97B 5.55B 370B 5.68B 38.06B 14.73B 183B 14.71B 14.38B 633B 25.74B 3.92B 3.44B 3.18B 2.97B 5.56B 370B 5.68B 38.1B 14.75B 183B 14.73B 14.4B 634B
Net income 4.71B 718M 630M 581M 544M 1.02B 67.75B 1.04B 6.97B 2.7B 33.46B 2.7B 2.64B 116B 4.81B 733M 643M 593M 555M 1.04B 69.14B 1.06B 7.12B 2.75B 34.15B 2.75B 2.69B 118B
Net Debt 4.1B 625M 548M 506M 473M 885M 58.94B 905M 6.07B 2.35B 29.11B 2.35B 2.29B 101B -30.08M -4.58M -4.02M -3.71M -3.47M -6.5M -433M -6.64M -44.53M -17.24M -214M -17.21M -16.83M -741M
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
26-06-26 €5.640 -1.66%
26-06-25 €5.735 -0.09%
26-06-24 €5.740 -0.43%
26-06-23 €5.765 +3.13%
26-06-22 €5.590 +0.81%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.00DKK
Average target price
47.21DKK
Spread / Average Target
+12.40%

Quarterly revenue - Rate of surprise